LLY · 10-Q · 2026Q2 · Full report
Manufacturing and Capital Expenditure Program
ELI LILLY & Co · 2026-08-05 · Importance 37 · Surprise 42 · In source text
Lilly is investing in global facilities to manufacture existing and future products. These investments increased capital expenditures and are expected to produce meaningfully higher capital expenditures in the near term. Additional manufacturing capacity for incretin products is expected to become operational over the next several years. The expansion is intended to support anticipated demand for Mounjaro, Zepbound, Foundayo, and prospective products.
Key facts
- The company is making investments in global facilities to manufacture existing and future products, which have increased capital expenditures and will result in meaningfully higher capital expenditures in the near term. source
- The company had increased capital expenditures and expects meaningfully higher capital expenditures in the near term to support investments in global manufacturing facilities. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | — | The company is making investments in global facilities to manufacture existing and future products, which have increased capital… |
| assets | positive | committed | — | The company is making investments in global facilities to manufacture existing and future products, which have increased capital… |